For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $0.67 in the prior trading day, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed at $0.63, down -4.84%. In other words, the price has decreased by -$4.84 from its previous closing price. On the day, 1.83 million shares were traded.
Ratios:
Our goal is to gain a better understanding of IRWD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1.31. For the most recent quarter (mrq), Quick Ratio is recorded 3.34 and its Current Ratio is at 3.34.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 16 ’25 when MCCOURT Thomas A sold 13,353 shares for $0.58 per share. The transaction valued at 7,745 led to the insider holds 1,147,281 shares of the business.
Gaskins Tammi L sold 2,563 shares of IRWD for $1,487 on May 16 ’25. The Chief Commercial Officer now owns 242,596 shares after completing the transaction at $0.58 per share. On May 19 ’25, another insider, MCCOURT Thomas A, who serves as the Officer of the company, bought 14,661 shares for $0.59 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.32.
Stock Price History:
Over the past 52 weeks, IRWD has reached a high of $7.11, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is -15.04%, while the 200-Day Moving Average is calculated to be -76.62%.
Shares Statistics:
A total of 161.81M shares are outstanding, with a floating share count of 155.78M. Insiders hold about 3.73% of the company’s shares, while institutions hold 96.62% stake in the company.
Earnings Estimates
The company has 2.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.13, with high estimates of $0.14 and low estimates of $0.12.
Analysts are recommending an EPS of between $0.21 and $0.16 for the fiscal current year, implying an average EPS of $0.19. EPS for the following year is $0.44, with 4.0 analysts recommending between $1.12 and $0.0.
Revenue Estimates
5 analysts predict $62.02M in revenue for the current quarter. It ranges from a high estimate of $68.3M to a low estimate of $54M. As of the current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $94.4MFor the next quarter, 5 analysts are estimating revenue of $77.82M. There is a high estimate of $83.4M for the next quarter, whereas the lowest estimate is $69M.
A total of 5 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $274.5M, while the lowest revenue estimate was $264M, resulting in an average revenue estimate of $269.28M. In the same quarter a year ago, actual revenue was $351.41MBased on 5 analysts’ estimates, the company’s revenue will be $258.74M in the next fiscal year. The high estimate is $285.3M and the low estimate is $225M.
